Using platelet-rich plasma to treat neurotrophic keratopathy
Official title: Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
Run by Universidad Autonoma de Nuevo Leon · NCT04604834 · Data updated 2026-11-12
This study is testing whether using a special treatment made from your own blood can help people with neurotrophic keratopathy heal their corneas better than just using artificial tears alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 39 (estimated) |
| Sponsor | Universidad Autonoma de Nuevo Leon Academic / other |
| Locations | 1 site (Monterrey, Nuevo León) |
| Status | Recruiting |
| Started | November 1, 2020 |
| Main results expected | November 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT04604834 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with neurotrophic keratopathy who have corneal erosions and meet specific inclusion criteria related to their medical history.
✕Probably not a fit
Patients with other ocular surface pathologies that cause corneal erosions but do not involve corneal hyposensitivity may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of autologous platelet-rich plasma (APRP) in treating neurotrophic keratopathy, a condition that impairs corneal sensitivity and healing. Participants will be randomly assigned to receive either APRP combined with preservative-free artificial tears (PFAT), APRP alone, or PFAT alone in a crossover design over a total of 12 weeks. The goal is to determine which treatment combination leads to better healing outcomes for the cornea. A thorough ophthalmologic evaluation will be conducted before and during the treatment periods to monitor progress and any adverse effects.
Why it matters
Potential benefit: If successful, this treatment could significantly improve healing and comfort for patients suffering from neurotrophic keratopathy.
How similar studies have gone: While the use of platelet-rich plasma in ocular conditions is gaining interest, this specific approach for neurotrophic keratopathy is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with: * Neurotrophic keratopathy diagnosed by esthesiometry (defined as central corneal sensitivity ≤ 3cm using Cochet-Bonnet aesthesiometer). * Corneal erosions. * Neurotrophic keratopathy secondary to: diabetes mellitus, herpetic keratitis, microbial keratitis sequelae (bacteria, Acanthamoeba, fungi, herpes), limbal stem cell deficiency, chemical or thermic burn sequelae at least 3 months after the accident, ocular trauma with penetrating wound fixed at least 3 months before the trial, surgery carried out at least 3 month before the trial (including keratoplasty, laser in situ keratomileusis, phacoemulsification cataract surgery, extracapsular cataract extraction), adenoviral keratoconjunctivitis resolved at least 3 months the trial. Exclusion Criteria: * Patients diagnosed with: * Other ocular surface pathology presenting with corneal erosions but without corneal hyposensitivity. * Corneal epithelial defect with or without corneal hyposensitivity. * Pregnant women, homeless, migrants.
Where it's running
-
Departamento de Oftalmologia, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico Recruiting
Study contacts
- Principal investigator: Karim Mohamed-Noriega, M.D. — Hospital Universitario Dr. Jose E. Gonzalez
- Study coordinator: Karim Mohamed-Noriega, M.D.
- Email: karim.mohamednrg@uanl.edu.mx,drkmohamed1@gmail.com
- Phone: +52 8183469259
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MR-146 in Neurotrophic Keratopathy: a first-in-human dose escalation and blinded comparison
This study tests MR-146 to see if it’s safe and works for adults with stage 1 or 2 neurotrophic keratopathy.
-
Personalized High-Rate Fluid Removal Guided by Ultrasound in Hospitalized ESRD with Fluid Overload
This trial tests whether using ultrasound to guide a higher rate of fluid removal is as safe and effective as standard fluid removal for adults with end-stage kidney disease who are admitted for severe fluid overload.
-
Placing a plug in the upper tear duct when the lower tear duct is already closed
This will try placing a plug in the upper tear duct to see if it improves symptoms in adults with aqueous-deficient dry eye who already have their lower puncta closed.
-
Pecan nut oil to lower inflammation in adults with overweight
This will see if taking 30 g/day of cold-pressed pecan nut oil for 8 weeks can lower blood inflammation markers and improve blood sugar and cholesterol in adults with overweight (BMI 25–30).
-
Topical losartan eyedrops for corneal scarring
This trial will test whether losartan eye drops improve vision and reduce corneal scarring in adults with stable corneal scars.
-
Investigating the effects of proton pump inhibitors on patients with variceal bleeding and liver disease
This study is testing if giving a medication called omeprazole to adults with liver disease and variceal bleeding can help them have a better recovery while they are in the hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.